90. Retinitis pigmentosa Clinical trials / Disease details
Clinical trials : 130 / Drugs : 180 - (DrugBank : 41) / Drug target genes : 49 - Drug target pathways : 109
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04945772 (ClinicalTrials.gov) | July 13, 2021 | 15/6/2021 | Efficacy and Safety of of vMCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] | A Phase 2b Randomized, Double-Masked, Sham-Controlled, Study to Evaluate the Efficacy and Safety of Intravitreal Injection of vMCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] | Retinitis Pigmentosa;Retinitis;Retinal Diseases;Eye Diseases;Eye Diseases, Hereditary;Retinal Dystrophies;Retinal Degeneration | Biological: Gene Therapy Product-vMCO-010;Procedure: Sham Injection | Nanoscope Therapeutics Inc. | NULL | Active, not recruiting | 18 Years | N/A | All | 27 | Phase 2 | United States;Puerto Rico |